Evidence of human papilloma virus infection and its epidemiology in esophageal squamous cell carcinoma

Yao, Pin-Fang; Li, Guang-Can; Li, Jin; Xia, He-Shun; Yang, Xianghong; Huang, Huan-Yuan; Fu, You-Gao; Wang, Ruiqin; Wang, Xiyin; Sha, Ju-Wei

doi:10.3748/wjg.v12.i9.1352

Cited by 45 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other Asian countries also have high rates of esophageal SCC, with an increasing incidence in Taiwan and Japan [4][5][6]. Tobacco use, alcohol consumption, drinking hot mate tea, chewing betel quid, and human papillomavirus infection have all been suggested to increase the risk of esophageal SCC, which is most common in males [4,7].…”

Section: Introductionmentioning

confidence: 99%

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia

et al. 2021

View full text Add to dashboard Cite

Background Patients with esophageal squamous cell carcinoma (SCC) have limited treatment options. Blocking transforming growth factor-β (TGFβ), which can be overexpressed in these tumors, may enhance responses to programmed cell death protein 1/programmed death-ligand 1 [PD-(L)1] inhibitors. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of the TGFβ receptor II (TGFβRII) (a TGFβ "trap") fused to a human IgG1 monoclonal antibody blocking PD-L1. Objective The objective of this study was to investigate the safety and efficacy of bintrafusp alfa in Asian patients with pretreated, PD-L1-unselected esophageal SCC. Patients and MethodsIn a phase 1 study, Asian patients with pretreated esophageal SCC received bintrafusp alfa 1200 mg every 2 weeks until disease progression, unacceptable toxicity, or withdrawal. The primary endpoint was safety/tolerability with a goal of exploring clinical activity. Results By the database cutoff of August 24, 2018, 30 patients (76.7% had two or more prior anticancer regimens) received bintrafusp alfa for a median of 6.1 weeks; two remained on treatment. Nineteen patients (63.3%) had treatment-related adverse events, seven (23.3%) with grade 3/4 events, and there were no treatment-related deaths. The confirmed objective response rate (ORR) per independent review was 10.0% (95% confidence interval [CI] 2.1-26.5); responses lasted 2.8-8.3 + months. All responses occurred in immune-excluded tumors. Investigator-assessed confirmed ORR was 20.0% (95% CI 7.7-38.6). Median overall survival was 11.9 months (95% CI 5.7-not reached). Conclusions Bintrafusp alfa demonstrated a manageable safety profile and efficacy in Asian patients with pretreated esophageal SCC. Clinical Trials Registration NCT02699515.

show abstract

Section: Introductionmentioning

confidence: 99%

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia

et al. 2021

View full text Add to dashboard Cite

show abstract

“…However, other investigators have shown that HPV 16 infection has no significant effect on survival and does not improve survival after treatment (radiotherapy or chemotherapy) [24]. No correlation was found between HPV in esophageal squamous cell carcinoma tissues and in grade 1-3 esophageal squamous cell carcinoma cells [67]. In the study by Lyronis et al conducted at the University of Crete, no statistically significant correlation was found between the HPV status of the tumour samples and clinical parameters including gender, age of the patients, tobacco or alcohol use, differentiation grade of the lesions and stage of the disease [26].…”

Section: Hpv and Oesophageal Cancermentioning

confidence: 87%

Vaccination against Human Papilloma Virus (HPV): Epidemiological Evidence of HPV in Non-genital Cancers

Mammas

Sourvinos

Zaravinos

et al. 2010

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Recently, the vaccine against human papillomavirus (HPV) was introduced in the national vaccination programmes of several countries worldwide. The established association between HPV and the progression of cervical neoplasia provides evidence of the expected protection of the vaccine against cervical cancer. During the last two decades several studies have also examined the possible involvement of HPV in non-genital cancers and have proposed the presence of HPV in oesophageal, laryngeal, oropharyngeal, lung, urothelial, breast and colon cancers. The possible involvement of HPV in these types of cancer would necessitate the introduction of the vaccine in both boys and girls. However, the role of HPV in the pathogenesis of these types of cancer has yet to be proven. Moreover, the controversial evidence of the possible impact of the vaccination against HPV in the prevention of non-genital cancers needs to be further evaluated. In this review, we present an overview of the existing epidemiological evidence regarding the detection of HPV in non-genital cancers.

show abstract

“…In high-incidence areas of ESCC, other causal factors have been implicated, and there is increasing evidence that HPV 16 may be associated with ESCC in these high-risk areas. 7,18 In this study, we investigated the expression of p16 1NK4 and the possible role of high-risk strains of HPV in cases of ESCC in North American patients.…”

Section: Discussionmentioning

confidence: 99%

Assessment of Immunohistochemistry for p16INK4 and High-Risk HPV DNA by In Situ Hybridization in Esophageal Squamous Cell Carcinoma

et al. 2011

View full text Add to dashboard Cite

The role of high-risk human papillomavirus (HPV) in the pathogenesis of esophageal squamous cell carcinoma (ESCC) remains unclear. p16(INK4) is used as a surrogate marker to detect HPV-related tumors but has had discrepant results in ESCC. In this study, 32 cases of ESCC were examined to determine the relationship between p16(INK4) expression and high-risk HPV. All the tumors were stained by immunohistochemistry for p16(INK4). Tumors having p16(INK4) nuclear and/or nuclear and cytoplasmic expression were considered positive. Tumors positive for p16(INK4) expression were tested for high-risk HPV by in situ hybridization (ISH). In all, 20 cases of ESCC (63%) showed only cytoplasmic staining for p16(INK4), and 11 cases (34%) showed both cytoplasmic and nuclear staining for p16(INK4); 4 cases (13%) showed no staining for p16(INK4). None of the p16(INK4) -positive cases were positive for high-risk HPV by ISH. These results indicate that p16(INK4) expression in ESCC does not correlate with the presence of high-risk HPV DNA by ISH. High-risk HPV does not seem to play a major role in the carcinogenesis of ESCC in low-risk areas.

show abstract

Evidence of human papilloma virus infection and its epidemiology in esophageal squamous cell carcinoma

Abstract: HPV infection is high in esophageal carcinoma of Henan emigrants, local residents and patients in Hubei Cancer Hospital.HPV is closely related with esophageal squamous cell carcinoma. HPV infection may play an important role in esophageal squamous cell carcinoma.

Cited by 45 publications

References 10 publications

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia

Vaccination against Human Papilloma Virus (HPV): Epidemiological Evidence of HPV in Non-genital Cancers

Assessment of Immunohistochemistry for p16INK4 and High-Risk HPV DNA by In Situ Hybridization in Esophageal Squamous Cell Carcinoma

Contact Info

Product

Resources

About